The estimated Net Worth of Arnon Rosenthal is at least $39.6 million dollars as of 3 September 2024. Arnon Rosenthal owns over 26,499 units of Alector stock worth over $11,322,214 and over the last 5 years he sold ALEC stock worth over $21,438,112. In addition, he makes $6,854,340 as Chief Executive Officer, Co-Founder et Director at Alector.
Arnon has made over 13 trades of the Alector stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 26,499 units of ALEC stock worth $129,315 on 3 September 2024.
The largest trade he's ever made was selling 200,000 units of Alector stock on 8 November 2021 worth over $5,000,000. On average, Arnon trades about 49,782 units every 57 days since 2019. As of 3 September 2024 he still owns at least 1,948,746 units of Alector stock.
You can see the complete history of Arnon Rosenthal stock trades at the bottom of the page.
DR. Arnon Rosenthal Ph.D. serves as Chief Executive Officer, Co-Founder, Director of the Company. Dr. Rosenthal co-founded Annexon Biosciences, Inc. and served as its acting Chief Executive Officer from August 2011 to December 2014 and served as a member of the board of directors, including as Chairman from August 2011 to February 2017. Dr. Rosenthal co-founded Rinat Neuroscience Corporation (acquired by Pfizer Inc. in August 2006), and served as President, Chief Scientific Officer and as a member of the board of directors from August 2001 to August 2006. From January 1985 to August 2001, Dr. Rosenthal served in various roles at Genentech, Inc., where he ultimately served as Staff Scientist and was appointed as a permanent member of Genentech’s Research Review Committee where his team discovered the target for the cancer drug Erivedge. Dr. Rosenthal conducted his post-doctoral fellowship at Genentech, Inc. He holds a Ph.D. in biology from the Hebrew University of Jerusalem.
As the Chief Executive Officer, Co-Founder et Director of Alector, the total compensation of Arnon Rosenthal at Alector is $6,854,340. There are no executives at Alector getting paid more.
Arnon Rosenthal is 64, he's been the Chief Executive Officer, Co-Founder et Director of Alector since 2019. There are 3 older and 16 younger executives at Alector. The oldest executive at Alector, Inc. is Louis Lavigne, 72, who is the Lead Independent Director.
Arnon's mailing address filed with the SEC is C/O ALECTOR, INC., 131 OYSTER POINT BLVD., SUITE 600, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 5 years, insiders at Alector have traded over $148,873,269 worth of Alector stock and bought 20,000 units worth $500,000 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Advisors Llc Orbi Med Capit... et Terrance Mcguire. On average, Alector executives and independent directors trade stock every 17 days with the average trade being worth of $438,922. The most recent stock trade was executed by Marc Grasso on 3 September 2024, trading 7,297 units of ALEC stock currently worth $35,609.
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase Ib clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease; and 8 candidates in immuno-neurology/immuno-oncology field comprise ADP012, ADP016, ADP017, ADP023, ADP026, ADP122, ADP009, and ADP022. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
Alector executives and other stock owners filed with the SEC include: